The Signature, Derived From a Liquid Biopsy Test, has the Potential to Avoid the Complications of Repeated Needle Biopsies
ROTTERDAM, Netherlands–(BUSINESS WIRE)–Exosome Diagnostics, a developer of revolutionary biofluid-based molecular diagnostics, in collaboration with Brigham and Women’s Hospital, in Boston, Mass., presented initial discovery and validation data for a kidney transplant rejection signature at the International Society for Extracellular Vesicles (ISEV) Annual Meeting.
“These data show that exosomes are a promising new platform for biomarkers and can be used to monitor RNA and protein expression.”
Patients with end stage renal disease (ESRD) usually undergo transplantation, however as many as 20% of these patients develop acute kidney rejection. Methods for monitoring clinical rejection includes an increase in serum creatinine and urinary protein secretion. These methods are not very accurate and may not reflect subclinical rejection. Currently, the patients are often monitored by repeat biopsies that may result in increased complications and cost.
“A need exists for a liquid biopsy diagnostic test that is non-invasive and would allow for earlier diagnosis and treatment to minimize the amount of immunosuppression and avoid the complications associated with repeat biopsies,” said Jamil R. Azzi, MD, Director, Kidney Transplantation Fellowship Program, Assistant Professor, Harvard Medical School. “These data show that exosomes are a promising new platform for biomarkers and can be used to monitor RNA and protein expression.”
“We are thrilled to see the result of this collaboration,” added Johan Skog, PhD, Chief Scientific Officer of Exosome Diagnostics. “It is another example of how exosome RNA can be used to detect and monitor disease progression in a non-invasive way.”
“These data are one of many indications from which Exosome Diagnostics has utilized the power of its platform to expand beyond indications in oncology and develop diagnostic signatures that may be utilized in the clinic, as well as in the company’s companion diagnostic programs with external partners,” said John Boyce, President and CEO of Exosome Diagnostics. “The company’s isolation methodology, cell-free DNA and exosomal RNA in one step, analysis pipelines, and proprietary algorithms in combination allow for the elucidation of liquid biopsy data and rapid procurement of signatures.”
The potential of data presented at ISEV for a transplant rejection signature provides additional rationale as to why Exosome Diagnostics has been building the company around the best patented exosome isolation technology and platform. The company’s exosomal RNA technology began in cancer diagnostics, and may now hold promise in transplantation as well as other initiatives in cardiovascular, neurodegenerative, and inflammatory diseases. The sky is the limit, and patients worldwide will someday reap the rewards.
The platform will allow Exosome Diagnostics to continue bringing the best liquid biopsies to the clinic. The company has already launched ExoDx® Lung(ALK) in cancer diagnostics and we are excited for the upcoming launch of ExoDx® Prostate(IntelliScore) from two biofluids, blood and urine.
About Exosome Diagnostics
Exosome Diagnostics is a privately held company focused on developing and commercializing revolutionary biofluid-based diagnostics to deliver personalized precision healthcare that improves lives. The company’s novel exosome-based technology platform, ExoLution®, can yield comprehensive and dynamic molecular insights to transform how cancer and other serious diseases are detected, diagnosed, treated and monitored. Visit www.exosomedx.com to learn more.
Source – BusinessWire